UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (938) 938
science & technology (910) 910
life sciences & biomedicine (889) 889
rosuvastatin calcium (743) 743
male (693) 693
female (605) 605
rosuvastatin (548) 548
middle aged (541) 541
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (442) 442
fluorobenzenes - therapeutic use (424) 424
pyrimidines - therapeutic use (414) 414
aged (413) 413
sulfonamides - therapeutic use (412) 412
statins (389) 389
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (337) 337
pharmacology & pharmacy (321) 321
cardiovascular system & cardiology (294) 294
fluorobenzenes - adverse effects (286) 286
pyrimidines - adverse effects (278) 278
sulfonamides - adverse effects (275) 275
treatment outcome (272) 272
adult (270) 270
cardiac & cardiovascular systems (260) 260
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (246) 246
fluorobenzenes - administration & dosage (213) 213
pyrimidines - administration & dosage (205) 205
cholesterol, ldl - blood (203) 203
sulfonamides - administration & dosage (202) 202
cholesterol (200) 200
abridged index medicus (165) 165
antilipemic agents (158) 158
hypercholesterolemia - drug therapy (158) 158
risk factors (152) 152
atorvastatin calcium (151) 151
drug therapy (151) 151
lipids (148) 148
cardiovascular disease (147) 147
general & internal medicine (142) 142
medicine, general & internal (140) 140
animals (136) 136
cardiovascular (136) 136
dose-response relationship, drug (133) 133
double-blind method (129) 129
fluorobenzenes - pharmacology (125) 125
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (120) 120
sulfonamides - pharmacology (120) 120
pyrimidines - pharmacology (119) 119
drug therapy, combination (117) 117
rosuvastatin calcium - therapeutic use (117) 117
atorvastatin (116) 116
rosuvastatin calcium - administration & dosage (114) 114
dosage and administration (110) 110
drug interactions (109) 109
care and treatment (106) 106
rosuvastatin calcium - adverse effects (106) 106
research (102) 102
heptanoic acids - therapeutic use (101) 101
prospective studies (101) 101
analysis (100) 100
pyrroles - therapeutic use (100) 100
cardiovascular diseases - prevention & control (98) 98
aged, 80 and over (96) 96
anticholesteremic agents - therapeutic use (96) 96
nutritional and metabolic diseases (94) 94
atherosclerosis (91) 91
dyslipidemias - drug therapy (91) 91
cardiovascular diseases (90) 90
hypercholesterolemia (90) 90
statin (90) 90
clinical trials (88) 88
time factors (85) 85
low density lipoproteins (82) 82
cardiology (81) 81
hydroxymethylglutaryl-coa reductase inhibitors - pharmacokinetics (78) 78
internal medicine (78) 78
simvastatin - therapeutic use (78) 78
biomarkers - blood (77) 77
fluorobenzenes - pharmacokinetics (75) 75
health aspects (75) 75
simvastatin (75) 75
randomized controlled trials as topic (73) 73
follow-up studies (72) 72
hyperlipidemias - drug therapy (72) 72
cholesterol - blood (71) 71
diabetes (71) 71
peripheral vascular disease (69) 69
pharmacokinetics (69) 69
young adult (69) 69
medicine & public health (67) 67
pyrimidines - pharmacokinetics (67) 67
triglycerides - blood (66) 66
coronary heart disease (63) 63
sulfonamides - pharmacokinetics (63) 63
cholesterol, hdl - blood (62) 62
lipids - blood (62) 62
ezetimibe (61) 61
hypercholesterolemia - blood (61) 61
anticholesteremic agents - administration & dosage (59) 59
rats (59) 59
heptanoic acids - administration & dosage (58) 58
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1080) 1080
Russian (5) 5
German (4) 4
Spanish (4) 4
Chinese (3) 3
French (3) 3
Italian (3) 3
Portuguese (3) 3
Dutch (2) 2
Japanese (2) 2
Czech (1) 1
Hungarian (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Pharmacological research, ISSN 1043-6618, 09/2011, Volume 64, Issue 3, pp. 180 - 186
.... However, it is not clear that the purported effectiveness of statins in neurodegenerative disorders is directly related to cholesterol-lowering effects of these agents... 
Alzheimer disease | Pleiotropic functions | Statins | Statins as Janus molecules | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Fatty Acids, Monounsaturated - pharmacology | Lovastatin - pharmacology | Heptanoic Acids - therapeutic use | Humans | Heptanoic Acids - adverse effects | Neurodegenerative Diseases - drug therapy | Quinolines - pharmacology | Fluorobenzenes - pharmacology | Fatty Acids, Monounsaturated - therapeutic use | Fatty Acids, Monounsaturated - adverse effects | Pyrroles - adverse effects | Indoles - pharmacology | Pyrroles - therapeutic use | Heptanoic Acids - pharmacology | Lovastatin - therapeutic use | Lovastatin - adverse effects | Alzheimer Disease - drug therapy | Rosuvastatin Calcium | Pyrimidines - pharmacology | Cholesterol - metabolism | Sulfonamides - pharmacology | Atorvastatin Calcium | Pyrroles - pharmacology | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Indoles - adverse effects | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Indoles - therapeutic use | Fluorobenzenes - adverse effects | Quinolines - therapeutic use | Fluorobenzenes - therapeutic use | Quinolines - adverse effects | Alzheimer's disease | Neuroprotection | Neurotoxicity | Neurodegenerative diseases | statins | Dyslipidemia | Clinical trials | Age | Cholesterol | Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 05/2016, Volume 374, Issue 21, pp. 2032 - 2043
... – 4 Therefore, combined lowering of LDL cholesterol and blood pressure can potentially have a bigger effect in reducing cardiovascular events than either intervention alone... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Risk Factors | Rosuvastatin Calcium - adverse effects | Antihypertensive Agents - administration & dosage | Hypertension - drug therapy | Male | Hydrochlorothiazide - administration & dosage | Rosuvastatin Calcium - administration & dosage | Antihypertensive Agents - adverse effects | Medication Adherence | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Benzimidazoles - administration & dosage | Tetrazoles - administration & dosage | Cardiovascular Diseases - epidemiology | Cholesterol, LDL - blood | Female | Aged | Drug Therapy, Combination | Care and treatment | Usage | Clinical trials | Rosuvastatin | Dosage and administration | Cardiovascular diseases | Risk factors | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | Antihypertensives | Cardiovascular disease | Lipids | Hydrochlorothiazide | Low density lipoprotein | Cholesterol | Disease prevention | Blood pressure | Health risk assessment | Drug therapy | Heart diseases | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2007, Volume 357, Issue 22, pp. 2248 - 2261
In this clinical trial, rosuvastatin was compared with placebo in elderly patients with systolic, ischemic heart failure. Although rosuvastatin significantly... 
TRIAL | SURVIVAL | EVENTS | MYOCARDIAL-INFARCTION | CHOLESTEROL LEVELS | MERIT-HF | DISEASE | PRAVASTATIN | DEATH | STATINS | UMCG Approved | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Single-Blind Method | Follow-Up Studies | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Systole | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Heart Failure - etiology | Proportional Hazards Models | Rosuvastatin Calcium | Treatment Outcome | Heart Failure - drug therapy | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Myocardial Ischemia - complications | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Fluorobenzenes - therapeutic use | Heart failure | Placebos | Rosuvastatin | Dosage and administration | Drug therapy | Comparative analysis | Cardiovascular disease | Heart attacks | Index Medicus | Abridged Index Medicus | Cardiovascular Diseases | MEDICIN OCH HÄLSOVETENSKAP | Myocardial Ischemia | epidemiology | Pyrimidines | Heart Failure | Hydroxymethylglutaryl-CoA Reductase Inhibitors | MEDICAL AND HEALTH SCIENCES | drug therapy | complications | Fluorobenzenes | Hospitalization | etiology | statistics & numerical data | Sulfonamides | mortality | adverse effects | therapeutic use
Journal Article
The New England journal of medicine, ISSN 1533-4406, 12/2011, Volume 365, Issue 22, pp. 2078 - 2087
In this trial, intravascular ultrasonography was used to compare the effects of atorvastatin versus rosuvastatin on regression of coronary atherosclerosis... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Coronary Vessels - diagnostic imaging | Heptanoic Acids - therapeutic use | Humans | Middle Aged | Ultrasonography, Interventional | Male | Heptanoic Acids - adverse effects | Coronary Artery Disease - pathology | Pyrroles - adverse effects | Cholesterol, LDL - blood | Female | Pyrroles - therapeutic use | Coronary Vessels - pathology | Double-Blind Method | Rosuvastatin Calcium | Coronary Artery Disease - drug therapy | Anticholesteremic Agents - adverse effects | Disease Progression | Atorvastatin Calcium | Coronary Artery Disease - diagnostic imaging | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Pyrimidines - adverse effects | Cholesterol, HDL - blood | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Fluorobenzenes - therapeutic use | Drugs | Rosuvastatin | Dosage and administration | Product/Service Evaluations | Drug therapy | Atherosclerosis | Lipoproteins (low density) | Clinical trials | Cardiovascular disease | Patients | Cholesterol | Studies | Side effects | Ultrasonic imaging | Arteriosclerosis | Atorvastatin | Heart diseases | Lipoproteins (high density) | Ultrasound | Statins | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
The American journal of cardiology, ISSN 0002-9149, 07/2003, Volume 92, Issue 2, pp. 152 - 160
Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2008, Volume 359, Issue 21, pp. 2195 - 2207
Journal Article